Creo Medical Group (LSE:CREO) ROCE % : -30.66% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Creo Medical Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Creo Medical Group's annualized ROCE % for the quarter that ended in Dec. 2023 was -30.66%.

Creo Medical Group ROCE % Historical Data

The historical data trend for Creo Medical Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Creo Medical Group ROCE % Chart

Creo Medical Group Annual Data

Trend

Feb14

Feb15

Feb16

Jun17

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-38.00

-29.55

-38.60

-44.13

-38.71

Creo Medical Group Semi-Annual Data
	Feb14	Feb15	Feb16	Dec16	Jun17	Dec17	Jun18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial												-53.39	-42.47	-45.76	-38.93	-30.66

Creo Medical Group ROCE % Calculation

Creo Medical Group's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-24.1	/	( ( (75.2 - 17.4)	+	(76.6 - 9.9) )	/ 2 )
	=	-24.1	/	( (57.8	+	66.7)	/ 2 )
	=	-24.1	/	62.25
	=	-38.71 %

Creo Medical Group's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-22	/	( ( (88.7 - 11.9)	+	(76.6 - 9.9) )	/ 2 )
	=	-22	/	( ( 76.8	+	66.7 )	/ 2 )
	=	-22	/	71.75
	=	-30.66 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Creo Medical Group (LSE:CREO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Creo Medical Group ROCE % Related Terms

Thank you for viewing the detailed overview of Creo Medical Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Creo Medical Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Creo Medical Group PLC (LSE:CREO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

1RC:Germany

Address

Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH

Website

https://www.creomedical.com

Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from Europe and the rest from the United Kingdom and the rest of the world.

Creo Medical Group Headlines

No Headlines